Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
122.81
+4.96 (+4.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Uncover the latest developments among S&P500 stocks in today's session.
October 17, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Via
Chartmill
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
October 17, 2025
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication.
Via
Benzinga
Which S&P500 stocks are moving on Friday?
October 17, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via
Chartmill
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
October 17, 2025
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market...
Via
MarketMinute
Topics
Retirement
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’
October 12, 2025
Via
Stocktwits
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
October 15, 2025
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes.
Via
Benzinga
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
October 15, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Jerry Pinkas Earns Certified Probate Specialist Designation, Elevating Compassionate Real Estate Expertise for South Carolina Families
October 13, 2025
Via
Get News
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
October 13, 2025
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy.
Via
Benzinga
Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'
October 13, 2025
On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade.
Via
Benzinga
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
October 13, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
3 S&P 500 Stocks We Approach with Caution
October 10, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...
Via
StockStory
Topics
Intellectual Property
Stocks
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
October 09, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Breaking Down Gilead Sciences: 6 Analysts Share Their Views
October 08, 2025
Via
Benzinga
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike
October 08, 2025
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.
Via
Investor's Business Daily
Gilead Sciences Inc (NASDAQ:GILD) Presents a Compelling Case for Value Investors
October 08, 2025
Gilead Sciences (GILD) presents a strong value investing case with a low P/E ratio, high profitability, and solid cash flow, suggesting the stock may be undervalued.
Via
Chartmill
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
October 07, 2025
Via
Benzinga
Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway
October 06, 2025
The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036.
Via
Stocktwits
Topics
Intellectual Property
Gilead Reaches Settlement To Block Biktarvy Generics Until 2036
October 06, 2025
Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036.
Via
Benzinga
Topics
Intellectual Property
Telecom Stocks Rattled After Verizon Unexpectedly Names Dan Schulman New CEO
October 06, 2025
The appointment is effective immediately, replacing Hans Vestberg who has led Verizon since 2018.
Via
Investor's Business Daily
Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump
October 06, 2025
The company is well known for its HIV treatment, Biktarvy. Biktarvy accounted for more than two-thirds of Gilead's HIV June-quarter sales.
Via
Investor's Business Daily
Topics
Intellectual Property
Discover the top S&P500 movers in Monday's pre-market session.
October 06, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Via
Chartmill
2 Surefire Dividend Stocks to Buy for the Long Haul
October 04, 2025
Both have crushed the market in 2025.
Via
The Motley Fool
Topics
Economy
Government
Intellectual Property
Is Gilead Sciences Inc Gaining or Losing Market Support?
October 02, 2025
Via
Benzinga
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap
October 02, 2025
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via
Benzinga
Market Whales and Their Recent Bets on GILD Options
October 02, 2025
Via
Benzinga
2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off
October 01, 2025
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...
Via
StockStory
Topics
Credit Cards
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
September 29, 2025
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...
Via
MarketMinute
U.S. Government Teeters on Brink of Shutdown: Markets Brace for Uncertainty Amidst Data Blackout Fears
September 29, 2025
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a...
Via
MarketMinute
Topics
Bonds
Economy
Government
3 Unpopular Stocks We Approach with Caution
September 29, 2025
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.